ACHIEVE Trials Demonstrate Comparative Benefits of Novel, Small-Molecule Oral GLP-1 RA, Expanding Oral Treatment Options for Patient Population in Need of Alternative Solutions

First Head-to-Head Trial Compares Two Oral GLP-1 RAs Effects on Glucose Control and Weight Changes in Type 2 Diabetes NEW ORLEANS, June 8, 2026 /PRNewswire/ -- New data show the benefits of orforglipron, the first oral, small molecule, non-peptide glucagon-like peptide-1 receptor agonist...